A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065 [M16-066] A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Ex ...
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065 [M16-066] A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Ex ...
Ulcerative Colitis (UC)
Intervention name : Risankizumab (Genetical Recombination) INN of the intervention : risankizumab Dosage And administration of the intervention : SC/IV Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - Intervention name : Risankizumab (Genetical Recombination) INN of the intervention : risankizumab Dosa ...
AbbVie GK
NULL
recruiting
16
80
BOTH
70
Phase 3
Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy [M16-067] A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy ...
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy [M16-067] A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy ...
Ulcerative Colitis (UC)
Intervention name : Risankizumab (Genetical Recombination) INN of the intervention : risankizumab Dosage And administration of the intervention : SC/IV Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - Intervention name : Risankizumab (Genetical Recombination) INN of the intervention : risankizumab Dosa ...
AbbVie GK
NULL
recruiting
16
80
BOTH
65
Phase 2-3
Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa